Publications by authors named "A Sauerbier"
The effect of subthalamic stimulation (STN-DBS) on patients' personal satisfaction with life and their Parkinson's disease (PD) treatment is understudied, as is its correlation with quality of life (QoL). Therefore, we tested the hypothesis that STN-DBS for PD enhances satisfaction with life and treatment. In a prospective, multicenter study with a 6-month follow-up involving 121 patients, we measured the main outcomes using the Satisfaction with Life and Treatment Scale (SLTS-7).
View Article and Find Full Text PDFCatechol-O-methyltransferase inhibitors (COMT-Is) have significantly improved the quality of life and symptom management for those at advanced stages of Parkinson's Disease (PD). Given that PD is one of the fastest-growing neurodegenerative diseases worldwide, there is a need to establish a clear framework for the systematic distribution of COMT-Is, considering inter-individual and intra-individual variations in patient response. One major barrier to this is the underrepresentation of ethnic minority participants in clinical trials investigating COMT-Is.
View Article and Find Full Text PDFBackground: Stigma is a relevant aspect of Parkinson's disease (PD). Specific stigma tools are needed to address the complex construct of stigma in PD comprehensively.
Objective: To test the dimensionality and psychometric properties of the newly developed Parkinson's Disease Stigma Questionnaire (PDStigmaQuest).
The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson's disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively.
View Article and Find Full Text PDFArticle Synopsis
- Deep brain stimulation (STN-DBS) is a treatment for people with advanced Parkinson's disease that helps with movement problems, but results can be different for each person.
- Researchers studied the brain scans of 49 Parkinson's patients to see if certain brain measurements could predict how well they would do in areas not just related to movement after treatment.
- They found that while losing brain volume in some areas like the frontal cortex linked to worse motor outcomes, it didn't really help predict non-motor issues, meaning it might not be super helpful for choosing which patients should get the treatment.